ANAB

Anaptysbio Inc

• Simply Wall St·6h ago

  Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Gains

• TipRanks·9h ago

  Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)

• TipRanks·4d ago

  J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)

• TipRanks·6d ago

  AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar

• PUBT·6d ago

  AnaptysBio shifts fiscal year-end to June 30 from Dec. 31

• Simply Wall St·05/16 09:40

  AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model

• Seeking Alpha·05/16 05:55

  Forte Biosciences: Targeting Celiac Disease

• TipRanks·05/15 16:45

  AnaptysBio price target raised to $90 from $85 at Leerink

• TipRanks·05/15 15:20

  Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA), Cormedix (CRMD) and AnaptysBio (ANAB)

• Reuters·05/15 02:59

  ANAPTYSBIO INC <ANAB.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $90 FROM $85

• TipRanks·05/14 06:02

  AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow

• Simply Wall St·05/13 23:40

  AnaptysBio (ANAB) Swings Back To Q1 Loss Per Share Challenging Recent Profitability Hopes

• Dow Jones·05/13 14:41

  AnaptysBio Is Maintained at Buy by UBS

• Benzinga·05/13 14:31

  UBS Maintains Buy on AnaptysBio, Raises Price Target to $76

• Dow Jones·05/13 14:20

  AnaptysBio Is Maintained at Overweight by Barclays